Maggie L. Shaw

This study investigated how an initial diagnosis influences delivery of second opinions concerning skin cancers, including the possibility of an incorrect diagnosis.

The usefulness of sentinel lymph node (SLN) biopsy was investigated among patients with melanoma and SLN metastases.

The REVEAL-HF study investigated using risk scores to improve patient outcomes through targeted interventions, including treatment initiation and intensity, end-of-life care, and hospitalization and mortality risks.

Gary Owens, MD, president of Gary Owens Associates, addresses how payers can improve outcomes for persons who have pulmonary arterial hypertension (PAH).

Anchalee Avihingsanon, MD, PhD, HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand, is principal investigator of the ALLIANCE trial from Gilead.

This study investigated the potential for postoperative recurrence of chronic rhinosinusitis with nasal polyps (CRSwNP) as measured against B7-H4 expression.

In this case report, a 50-year-old female patient, with a family history of lung cancer, received a diagnosis of multiple myeloma (MM) following presentation with an apical lung mass.

Previous studies have produced heterogeneous results on next-generation flow (NGF)-based minimal residual disease (MRD) detection, despite improvements to the method’s reproducibility and sensitivity, prompting the present authors to investigate its clinical utility.

This new study evaluated outcomes following add-on dupilumab to treat severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP).

This new study investigated keratinocyte carcinoma mortality and morbidity rates following pediatric solid organ transplant. Little is known on these associations in pediatric patients; more is known of these outcomes among adult patients.

Garo Owens, MD, is president of Gary Owens Associates, and here he discusses optimizing treatment goals for patients with pulmonary arterial hypertension (PAH) while reducing care costs.

The ALLIANCE trial is the first randomized blinded trial to investigate tenofovir alafenamide vs tenofovir disoproxil fumarate in treatment-naive individuals who have comorbid HIV/hepatitis B virus (HBV) infection.

This new study, conducted among persons living with melanoma in situ, investigated the possibility of identifying clinicopathological predictors of local recurrence.

A team of investigators from across the United States investigated a potential connection between patients’ health insurance literacy and their reported financial hardship.

This prospective study on reflectance confocal microscopy, a high-resolution and noninvasive form of imaging for skin cancer, investigated if the diagnostic method could improve accuracy results by 30% following dermoscopy.

Enrique Ocio, MD, PhD, Hematology Department head, Marqués de Valdecilla University Hospital, Santander, Spain, discussed the convenience seen in subcutaneous isatuximab.

Thanos Zomas, MD, global medical lead for lymphoma and leukemia and for the Adcetris Program, Takeda Oncology, discussed results of the ECHELON-1 trial.

Hope S. Rugo, MD, FASCO, professor of medicine and director, Breast Oncology and Clinical Trials Education, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, said PALOMA-2 results don’t match what she has seen in practice.

Although melanoma incidence has been reported in Europe overall for the past several decades, specific numbers on the cancer’s incidence in Finland, as well as disease trends, have remained unknown.

Joel Neal, MD, PHD, associate professor, Division of Oncology, Stanford Cancer Institute, discussed phase 1b results in COSMIC-021 in non-small cell lung cancer.

In part 2 of our interview with Anne McCall, PhD, provost and senior vice president for academic affairs at Xavier University of Louisiana, she discusses in greater detail the university’s 3-year partnership with Takeda, in particular how the directions it goes in will be influenced by the history of unequal health care delivery in the state.

Kim A. Reiss, MD, assistant program director, assistant professor of medicine, Hospital of the University of Pennsylvania, Philadelphia, discusses 2 abstracts presented during ASCO.

Randall A. Oyer, MD, medical director of the Ann B. Barshinger Cancer Institute, medical director of oncology, and medical director of the Cancer Risk Evaluation Program, Lancaster General Health, discusses recommendations to improve diversity in clinical trials.

This new study investigated the ability of a multiparametric model to calculate risk of eosinophilic chronic rhinosinusitis with nasal polyps (ECRSwNP) by comparing its clinical characteristics with noneosinophilic CRSwNP.